Multiple Myeloma | Specialty

The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.

Isatuximab Plus VRd Wins Japanese Approval for Transplant-Ineligible, Newly Diagnosed Myeloma

February 25th 2025

Isatuximab plus VRd has been approved in Japan for transplant-ineligible, newly diagnosed multiple myeloma.

Novel Bispecific Antibodies in Development for Relapsed/Refractory Multiple Myeloma

February 25th 2025

Panelists briefly discuss the results of studies evaluating additional bispecific regimens in the later-stage relapsed/refractory multiple myeloma space, including cevostamab, ABBV-383 plus daratumumab-dexamethasone (Dd), and linvoseltamab in the LINKER-MM1 trial.

Recent Insights Into Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

February 25th 2025

Panelists comment on recent updates from the International Myeloma Society/ American Society of Hematology (IMS/ASH) 2024 annual meetings, discussing the efficacy of approved bispecific antibodies in relapsed/refractory multiple myeloma (R/R MM), including teclistamab (MajesTEC-1), elranatamab (MagnetisMM-3), and talquetamab (MonumenTAL-1).

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Treatment Overview in Later-Stage Relapsed/Refractory Multiple Myeloma

February 18th 2025

Panelists provide a high-level overview of the treatment landscape for later-stage relapsed/refractory multiple myeloma (R/R MM), discussing the latest therapies and emerging treatment options for this patient population.

The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma

February 18th 2025

Panelists discuss the key toxicities influencing chimeric antigen receptor (CAR) T-cell therapy selection for early relapsed/refractory multiple myeloma (R/R MM), the transition to community care post treatment, strategies for managing toxicities, the future of CAR T in early R/R MM, and the impact of emerging data on treatment sequencing, along with insights from the DREAMM-7 and DREAMM-8 studies and improving the CAR T process in academic and community settings.

Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance

February 16th 2025

Ide-cel proved feasible and effective in boosting response in patients with myeloma with suboptimal response to standard frontline therapy.

Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma

February 15th 2025

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Joseph on the Effects of Resistance Training on Fatigue and Pain in Multiple Myeloma

February 14th 2025

Janine Joseph, MS, MBA, discusses the effects of resistance training interventions on fatigue and pain levels in patients with multiple myeloma.

FDA Grants Orphan Drug Designation to OPN-6602 for R/R Multiple Myeloma

February 13th 2025

OPN-6602, a small molecule EP300/CBP inhibitor, received orphan drug designation for multiple myeloma.

FDA Accepts BLA Resubmission for Linvoseltamab in R/R Multiple Myeloma

February 11th 2025

A resubmitted biologics license application for linvoseltamab in relapsed/refractory multiple myeloma is under review by the FDA.

Weighing CAR T Toxicity Profiles in Early R/R MM

February 11th 2025

Panelists discuss how recent data from the KarMMa-3 study influence the decision to treat early-stage relapsed/refractory multiple myeloma (R/R MM) with idecabtagene vicleucel (ide-cel), as well as the key toxicities considered when selecting chimeric antigen receptor (CAR) T-cell therapy. They also explore how these toxicities impact the transition of patients back to the community setting post CAR T and share strategies for managing early- and late-stage toxicities.

CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial

February 11th 2025

Panelists discuss how recent data from the KarMMa-3 study inform the decision to treat early-stage relapsed/refractory multiple myeloma (R/R MM) with idecabtagene vicleucel (ide-cel), including insights from the updated analysis.

Five Under 5: Top Oncology Videos for the Week of 2/2

February 9th 2025

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Dr Lin on Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

February 7th 2025

Yi Lin, MD, PhD, discuses cilta-cel vs standard of care in patients with lenalidomide-refractory multiple myeloma.

Dr Phull on Real-World vs Trial Data for CAR T-Cell Therapy in R/R Multiple Myeloma

February 4th 2025

Pooja Phull, MD, highlights differences between real-world vs clinical trial data for cilta-cel vs ide-cel in relapsed/refractory multiple myeloma.

Quadruplet Regimens Stand Strong in Newly Diagnosed Multiple Myeloma

February 4th 2025

Experts break down emerging data for the use of quadruplet regimens in newly diagnosed multiple myeloma.

Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

February 4th 2025

Panelists discuss the latest efficacy data from the CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (R/R MM), the significance of minimal residual disease (MRD) negativity, and how real-world and patient-reported outcomes influence the decision to use chimeric antigen receptor (CAR) T-cell therapy for early-stage R/R MM. They also compare standard-of-care idecabtagene vicleucel (ide-cel) and cilta-cel in this patient population.

Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM

February 4th 2025

Panelists discuss their optimal strategies for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T in the treatment of relapsed/refractory multiple myeloma (R/R MM).